<DOC>
	<DOC>NCT02265666</DOC>
	<brief_summary>The objective of the present study is to investigate the relative bioavailability of BIIL 284 BS Tablet FF in comparison to the tablet C at a dose of 5 mg after a standard breakfast in healthy male volunteers</brief_summary>
	<brief_title>Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS</brief_title>
	<detailed_description />
	<criteria>All participants are healthy males Age range from 21 to 50 years BrocaIndex: within + 20% of normal weight In accordance with Good Clinical Practice (GCP) and local legislation each volunteer is supposed to give their written informed consent prior to admission to the study Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders History of orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of a drug with a long halflife (&gt; 24 hours) within at least one month or less than ten halflives of the respective drug before enrollment in the study Use of any drugs which might influence the results of the trial (&lt;= one week prior to administration or during the trial) Participation in another trial with an investigational drug (&lt;= two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) Inability to refrain from smoking on study days Alcohol abuse (&gt; 60g/day) Drug abuse Blood donation (&gt;= 100 mL within four weeks prior to administration or during the trial) Excessive physical activities (within the last week before the study ) Any laboratory value outside the reference range of clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>